ArticleClinical & translational immunology2026
Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.
Article in Clinical & translational immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess neutralizing antibody responses to emerging SARS-CoV-2 variants. Methods: We explored SARS-CoV-2 neutralizing antibodies in140 adults participating in a longitudinal study of antibody responses to COVID vaccines. Participants reported monthly on vaccine doses, and SARS-CoV-2 infections. Serum was collected in December 2023 and April 2024 to determine neutralizing antibody to Wuhan ancestral strain and Omicron XBB.1.5 and JN.1 subvariants. Multivariate analysis assessed protective factors against a new SARS-CoV-2 infection between the two sampling times and 10 months follow up. Results: 74% had hybrid immunity and 26% vaccine only immunity at study entry. A neutralizing antibody response was detected in 99% to Wuhan ancestral strain compared to 86% and 79% respectively to Omicron XBB.1.5 and JN.1 subvariants. For those with detectable antibodies the levels decayed, faster in those with vaccine only immunity and to the JN.1 subvariant. Neither the presence or the level of neutralizing antibody to JN.1 was associated with protection with a new SARS-Cov-2 infection over the 10-month follow up period. Conclusion: Neutralizing antibody levels to Omicron JN.1 subvariant were identified in 79% overall but in only 56% with vaccine only immunity. The presence or level was not associated with protection form a new SARS-CoV-2 infection over 10-months. This data supports the development of pan-coronavirus vaccine to expand protection against emerging variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.